Lava Therapeutics to move Extraordinary General Meeting to early November

LAVA Therapeutics (LVTX) has decided to cancel the Extraordinary General Meeting of Shareholders scheduled to occur on September 30, 2025 to consider and approve certain matters related to the Company’s previously announced transaction with XOMA Royalty Corporation (XOMA), pursuant to which XOMA made an offer to purchase all of the issued and outstanding common shares in the capital of the Company. The Company is canceling the EGM to continue discussions with XOMA concerning the terms of the Transaction, including the Company’s estimated cash forecast and the consideration payable to the Company’s shareholders in the Transaction. Both the Company and XOMA Royalty remain committed to completing the Transaction. The EGM is expected to be reconvened by early November 2025.